CompletedNo phase
FFP Usage in Pediatric CV Surgery
Key facts
- Who runs it
- University of Alberta
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 431 people enrolled
- Started
- 28 Aug 2023
- Ended
- 8 Jul 2024
- Type of study
- Observational, 2 groups
- Record updated
- 19 September 2024
Who can take part
- Age
- Up to 18 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- pediatric patients between 4 and 8 kilograms undergoing congenital cardiac surgery with cardiopulmonary bypass
Who cannot take part
- Patients requiring FFP for heparin resistance and anti-thrombin III deficiency will be excluded
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
When small children undergo heart surgery with the heart-lung machine, in the past, blood products to help the blood clot such as Fresh Frozen Plasma (FFP) was routinely used in children under 10kg. With blood clot monitoring technology, we feel that it might not be necessary to expose all children to FFP. We want to determine if those children who did not receive FFP bleed more or require more blood products as compared to those who did receive FFP while on the heart lung machine.
The 2 groups in the trial
- FFP
Patients undergoing CPB receiving FFP
- no FFP
Patients undergoing CPB not receiving FFP
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Outcomes of Fresh Frozen Plasma Usage During Cardiopulmonary Bypass in Congenital Cardiac Surgery.
- Record updated
- 19 September 2024